ThredUp acquired Remix in July 2021, a $28.5 million deal designed to give it a foothold in the then-emerging European resale market, while providing the Bulgaria-based Remix with the resources to scale faster than it would on its own.

CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 7th Annual Evercore HealthCONx Conference in Miami on Tuesday, December 3, 2024, at 3:25 p.m. ET. For investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Evercore representative. About Remix TherapeuticsRemix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression

REM-422, a First-in-Class Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity as Monotherapy and in Combination in Preclinical Models of AML. WATERTOWN, Mass., Nov. 20, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced an upcoming oral presentation at the 66th ASH Annual Meeting taking place from December 7-10, 2024, in San Diego, CA. Results demonstrate oral dosing of REM-422, a selective mRNA degrader of the MYB oncogene, leads to robust anti-leukemic activity observed both as a monotherapy and in combination across a genetically diverse set of preclinical models of acute myeloid leukemia (AML), including eradication of AML blasts in engrafted patient-derived xenograft (PDX) models of AML. The presentation also highlights the differentiated mechanism of action of REM-422 as it can be combined effectively with other agents used in the treatment of AML/MDS and retains activity in cell models engineered with mutations known to confer resistance to other targeted agents. "The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix Therapeutics